Key Facts Every KVUE Investor Should Know Today

By Kim Brooks • Tuesday, August 06 15:10 • Permanent Link

Large-cap Consumer Discretionary company Kenvue has moved 14.0% so far today on a volume of 32,991,108, compared to its average of 22,133,661. In contrast, the S&P 500 index moved 2.0%.

Kenvue trades -3.87% away from its average analyst target price of $21.57 per share. The 12 analysts following the stock have set target prices ranging from $18.0 to $25.0, and on average have given Kenvue a rating of hold.

Anyone interested in buying KVUE should be aware of the facts below:

Kenvue's current price is 87.1% above its Graham number of $11.08, which implies that at its current valuation it does not offer a margin of safety
Kenvue has moved -22.2% over the last year, and the S&P 500 logged a change of 15.3%
Based on its trailing earnings per share of 0.78, Kenvue has a trailing 12 month Price to Earnings (P/E) ratio of 26.6 while the S&P 500 average is 28.21
KVUE has a forward P/E ratio of 16.9 based on its forward 12 month price to earnings (EPS) of $1.23 per share
The company has a price to earnings growth (PEG) ratio of 14.77 — a number near or below 1 signifying that Kenvue is fairly valued compared to its estimated growth potential
Its Price to Book (P/B) ratio is 3.74 compared to its sector average of 3.11
Kenvue Inc. operates as a consumer health company worldwide.
Based in Skillman, the company has 22,000 full time employees and a market cap of $39.7 Billion. Kenvue currently returns an annual dividend yield of 3.3%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.